Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

摘要

>Results. From April 2006 to April 2008, 42 patients were enrolled. The median age was 60 years (range, 32–76 years). The median duration of treatment was 5.2 months (range, 0.7–8.5 months), and a median of nine cycles was given per patient (range, 1–12 cycles). Five patients (11.9%) showed a CR, with a median duration of 23.1 months (95% confidence interval [CI], 10.8–39.7 months). The objective response rate was 80.9% (95% CI, 65.9%–91.4%). The median overall and progression-free survival times were 24.7 months (95% CI, 22.6 months to not reached) and 9.5 months (95% CI, 7.6–10.4 months), respectively. The most frequent grade 3–4 adverse events were diarrhea (52%), neutropenia (38%), and asthenia (32%).